← Eichor
Condition: Potentially Resectable Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Potentially Resectable

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06001658D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage II
Phase 3 · 1 location(s) · Guangdong Provincial People's Hospital · NCT07016126Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments
Phase N/A · 1 location(s) · Bristol-Myers Squibb · NCT06448793SIRT for Potentially Resectable HCC
NA · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05994859Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
Phase 1/Phase 2 · 1 location(s) · Yonsei University · NCT03694236Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
Phase N/A · 1 location(s) · Hunan Province Tumor Hospital · NCT04324151Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Tre
Phase 2 · 1 location(s) · Spanish Cooperative Group for the Treatment of Digestive Tum · NCT06207656Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
Phase 2 · 1 location(s) · Baylor Research Institute · NCT04926467Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT05503667Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Phase 1/Phase 2 · 2 location(s) · Baylor College of Medicine · NCT05932199A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After R
Phase 2 · 1 location(s) · Zeng Jian · NCT06424899Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
NA · 1 location(s) · Peking University Cancer Hospital & Institute · NCT04047953Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Poten
Phase 2/Phase 3 · 2 location(s) · Shanghai Zhongshan Hospital · NCT06796803A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable I
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05967182A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Ther
NA · 1 location(s) · Li Qiang · NCT07070076FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of P
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07012798Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Ca
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07323056The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
Phase 2/Phase 3 · 3 location(s) · Mara Veenstra, MD · NCT06355427Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06041477
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.